Latest News

Thursday, December 18, 2014 | Management/Leadership, SCHWIND eye-tech-solutions

New Head of Sales at Schwind Eye-Tech-Solutions

Starting January 1, 2015, Michael Fichtner, 52, will become the new head of sales at Schwind eye-tech-solutions, according to a company news release. He brings with him more than 25 years of int…

Read the full story

Thursday, December 18, 2014 | Clinical Trials

Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis

Aldeyra Therapeutics announced that an investigational new drug application (IND) to conduct phase 2 clinical testing of NS2 for the treatment of noninfectious anterior uveitis was submitted to the FD…

Read the full story

Thursday, December 18, 2014 | Acquisitions/Mergers

Shire Said to Weigh Offer for NPS as It Revisits Deals

Shire, looking to boost growth after its proposed sale to Abbvie Inc. collapsed, is considering a bid for NPS Pharmaceuticals, people familiar with the matter said. Shire is interested in Bedminster, …

Read the full story

Thursday, December 18, 2014 | Medical Studies

Groundbreaking Wireless Material May Restore Sight to Blind Retinas

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration. New progress …

Read the full story

Wednesday, December 17, 2014 | Glaucoma

Prevent Blindness Study Projects Number of Cases and Costs Related to Glaucoma to Soar

According to the 2014 Prevent Blindness “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems” report, more than 2.8 million Americans currently have glaucoma. Those n…

Read the full story

Wednesday, December 17, 2014 | Management/Leadership

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition

Actavis announced the planned senior management team that will lead the company following the close of the acquisition of Allergan, anticipated in the second quarter of 2015, according to a company ne…

Read the full story

Wednesday, December 17, 2014 | Medical Studies

The Human Eye Can See 'Invisible' Infrared Light

Any science textbook will tell you we can't see infrared light. Like X-rays and radio waves, infrared light waves are outside the visual spectrum. But an international team of researchers co-led b…

Read the full story

Tuesday, December 16, 2014 | Earnings & Financials

Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index

Aerie Pharmaceuticals announced that it has been selected for addition to the NASDAQ Biotechnology Index, which will become effective upon market open on Monday, December 22, 2014. The NASDAQ Biote…

Read the full story

Tuesday, December 16, 2014 | Medical Studies

Artificial Retina Steps Closer With Groundbreaking Wireless Material

A proof-of-concept study published in the journal Nano Letters, reports how a groundbreaking new material can activate brain neurons in response to light without the use of wires to an external source…

Read the full story

Tuesday, December 16, 2014 | Health Care

Vivek Murthy, MD, Confirmed as Surgeon General

The Senate today confirmed Vivek Murthy, MD, as the nation's next Surgeon General as Democrats took advantage of their soon-to-end majority status to overcome GOP opposition to President Barack Ob…

Read the full story

Monday, December 15, 2014 | Retina, Genentech

FDA Grants Breakthrough Therapy Designation for Lucentis for the Treatment of Diabetic Retinopathy

The FDA has granted breakthrough therapy designation for Lucentis (ranibizumab; Genentech) for the treatment of diabetic retinopathy, according to a company statement. A medicine may be designated …

Read the full story

Monday, December 15, 2014 | Miscellaneous

National Expert Panel Provides Recommendations for Vision Health Systems for Preschool Age Children

To address the need of an effective approach in helping to ensure the vision health of children across the country, the National Expert Panel (NEP) of the National Center for Children’s Vision a…

Read the full story

Monday, December 15, 2014 | Clinical Trials

Second Part of Can-Fite BioPharma's Glaucoma Phase 2 Study Has Been Approved in Bulgaria

Can-Fite BioPharma and its subsidiary, OphthaliX Inc., jointly announced the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second coh…

Read the full story

Monday, December 15, 2014 | Management/Leadership

Roche Says Head of Genentech Research Unit to Retire

Roche said the head of research operations at its subsidiary Genentech would retire at the end of the year, the latest in a string of executives to leave the Californian biotech unit. The Swiss firm s…

Read the full story

Monday, December 15, 2014 | Medical Studies

Stem Cell in Eye May Help Restore Vision Following Cornea Injury, Infection

Figures provided by the National Eye Institute reveal that corneal infectious diseases have compromised the sight of over 250 million people worldwide. Of these, 6 million have become blind. Results o…

Read the full story
Load More

Advertisement

 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $30.10  0.00% 
 Akorn, Inc. $38.41  0.00% 
 Alimera Sciences, Inc. $5.73  0.00% 
 Allergan, Inc. $212.18  0.00% 
 Avalanche $50.36  0.00% 
 Bayer $141.89  0.00% 
 Can-Fite Biopharma $3.47  0.00% 
 Carl Zeiss Meditec $20.41  0.39% 
 Cooper Companies, Inc. $162.28  0.00% 
 Escalon Medical Corp. $1.52  0.00% 
 Essilor International $110.25  0.00% 
 Imprimis Pharmaceuticals, Inc. $8.49  0.00% 
 InSite Vision, Inc. $0.21  0.00% 
 IRIDEX Corporation $8.81  0.00% 
 Johnson & Johnson $106.81  0.00% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $53.80  0.00% 
 Merck & Company, Inc. $58.98  0.00% 
 NicOx $1.98  -1.05% 
 NovaBay Pharmaceuticals, Inc. $0.63  0.00% 
 Novartis AG Common Stock $94.57  0.00% 
 Ocular Therapeutix $20.48  0.00% 
 Ophthotech Corporation $47.47  0.00% 
 Quantel $3.24  -2.99% 
 Regeneron $423.79  0.00% 
 Roche $36.90  0.00% 
 STAAR Surgical Company $9.22  0.00% 
 TearLab Corporation $2.45  0.00% 
 Thrombogenics $7.80  0.00% 
 Topcon Corporation $21.66  0.00% 
 Valeant Pharmaceuticals $143.00  0.00% 
 Xoma $4.25  0.00%